Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: S01EC04

Azopt(brinzolamide)

Glaucoma, Open-Angle;Ocular Hypertension

Marketing Authorisation Holder: Novartis Europharm Limited

EMA Authorisation: 09/03/2000

INN: brinzolamide

Indication

Azopt is indicated to decrease elevated intraocular pressure in: ocular hypertension; open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Azopt — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.